Skip to main content

Blackman Samuel C.'s Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Aug 19, 2024

Accession no.
0001415889-24-021621
Filed
Aug 19, 2024
Trade date
Aug 15-16, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $31.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Blackman Samuel C.CIK 0001863676Officer (HEAD OF R&D)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseAcquired+1,187––1,122,268Direct
Aug 15, 2024Common StockMOption exerciseAcquired+1,437––1,123,705Direct
Aug 15, 2024Common StockMOption exerciseAcquired+6,062––1,129,767Direct
Aug 16, 2024Common StockSSaleDisposed−2,232$14.00−$31,2481,127,535Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseDisposed−1,187$0.00$05,943Direct
Aug 15, 2024Common StockMOption exerciseDisposed−1,437$0.00$012,941Direct
Aug 15, 2024Common StockMOption exerciseDisposed−6,062$0.00$078,814Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)